Почетна › Многи мијелом › Њујорк
Kliničke studije za Многи мијелом u državi Њујорк
74 studija za Многи мијелом traži učesnike na lokacijama u državi Њујорк.
Gradovi u državi Њујорк
- New York City59 студија
- Queens19 студија
- New Rochelle14 студија
- Staten Island13 студија
- Greenburgh13 студија
- Rochester9 студија
- Buffalo9 студија
- The Bronx5 студија
- Albany4 студија
Zvanični tekst studije (na engleskom)
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Northwell Health/ RJ Zuckerberg Cancer Center, Lake Success
- North Shore University Hospital, Manhasset
- Long Island Jewish Medical Center, New Hyde Park
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06152575A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Icahn School of Medicine at Mount Sinai /ID# 251166, New York
- Memorial Sloan Kettering Cancer Center-Koch Center /ID# 251167, New York
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT05650632Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
- Roswell Park Cancer Institute, Buffalo
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT05312255Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
- Wilmot Cancer Center, Clinical Trial Office of the University of Rochester Medical Center, Rochester
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT06993675A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Weill Cornell Medicine/New York Presbyterian Hospital, New York
- New York Presbyterian Hospital Columbia University Medical Center, New York
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT05137054A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Memorial Sloan Kettering Cancer Center, New York
- Columbia University Medical Center, New York
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07393282A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Roswell Park Cancer Institute, Buffalo
- Mount Sinai Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- и још 1
Тражи се учесникФаза 4
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT05201781A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Hematology-Oncology Associates of CNY, East Syracuse
- Northwell Health Cancer Institute, Lake Success
- NYU Langone Hospital Long Island, Mineola
- и још 3
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT05552222A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Icahn School of Medicine at Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT05652335A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Mount Sinai Brooklyn, Brooklyn
- NYU Winthrop, Mineola
- Mount Sinai Chelsea, New York
- и још 3
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07258511A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Mount Sinai Medical Center, New York
- University of Rochester Medical Center, Rochester
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT04634552A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- и још 1
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT07099391Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- University of Rochester Medical Center, Rochester
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT06433947A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- The Tisch Cancer Institute/Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT07284758A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Perlmutter Cancer Center at NYU Langone Hospital, Brooklyn
- Memorial Sloan Kettering Cancer Center, New York
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT07280013AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, New York
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT06106945A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Weill Cornell Medical College, New York
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06615479A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214, New York
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06953960A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- MSK Commack, Commack
- MSK Westchester, Harrison
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT05623020Collection of Tissue Samples for Cancer Research
- Roswell Park Cancer Institute, Buffalo
Тражи се учесникОпсервациона студија
2 Months · Оба пола · Ажурирано 27. 10. 2026. · NCT00900198Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Icahn School of Medicine at Mount Sinai, New York
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT03761108A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT04973605Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
- Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT07725406A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Memorial Sloan-Kettering Cancer Center, New York
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT05651932A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, Great Neck
- Research Site, New York
- Research Site, New York
- и још 4
Тражи се учесникФаза 3
Узраст од 18 до 130 · Оба пола · Ажурирано 21. 10. 2026. · NCT07735637A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- Mount Sinai - The Tisch Cancer Institute /ID# 272470, New York
- Weill Cornell Medical College /ID# 272517, New York
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT06892522A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Icahn School of Medicine at Mount Sinai /ID# 277844, New York
- Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946, New York
- Weill Cornell Medicine Myeloma Center /ID# 278216, New York
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT07095452Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- David H. Koch Center for Cancer Care, New York
- Montefiore Medical Center PRIME, The Bronx
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT07648264A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- и још 1
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT07105059A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- New York Oncology Hematology, Albany
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06980480A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Consent only), Harrison
- Weill Cornell Medical Center (Data Analysis Only), New York
- и још 2
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT07249528AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, New York
- Research Site, Stony Brook
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT05850234Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Roswell Park Cancer Institute, Buffalo
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT06297226Limited-duration Teclistamab
- Columbia University, New York
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT05932680Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activity), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Mount Sinai Hospital, New York
- и још 2
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT06976476A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- и још 1
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT06055894A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
- и још 1
Тражи се учесникФаза 2
Узраст 60 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT06679829A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Albany
- Research Site, New York
- Research Site, New York
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 29. 9. 2026. · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- New York Oncology Hematology, Albany
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
- NYU Langone Health Manhattan, New York
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT07518186A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, New York
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT07073547Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.